Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Soleno Therapeutics Inc (SLNO)
Soleno Therapeutics Inc (SLNO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,018
  • Shares Outstanding, K 9,992
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,070 K
  • 60-Month Beta 0.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.96
Trade SLNO with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 91.51%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.62
  • Number of Estimates 1
  • High Estimate -0.62
  • Low Estimate -0.62
  • Prior Year -0.76
  • Growth Rate Est. (year over year) +18.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.69 +11.38%
on 09/07/23
5.61 -26.67%
on 08/29/23
-0.30 (-6.80%)
since 08/21/23
3-Month
3.69 +11.38%
on 09/07/23
5.61 -26.67%
on 08/29/23
-0.82 (-16.63%)
since 06/21/23
52-Week
0.85 +383.53%
on 12/15/22
6.20 -33.71%
on 06/05/23
+2.13 (+107.58%)
since 09/21/22

Most Recent Stories

More News
Soleno Therapeutics, Inc. (SLNO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Soleno Therapeutics, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

SLNO : 4.11 (+0.12%)
Three Healthcare Penny Stocks to Watch In The New Year

These three penny (and nickel) stocks in the healthcare sector have a lot of potential for 2023, and definitely worth watching.

ACRX : 0.7430 (-0.93%)
HAPP : 4.50 (+1.35%)
SLNO : 4.11 (+0.12%)
Pre-Market Brief: Stocks Mostly Lower as Economic Outlook Darkens, BoJ Policy Shift

March S&P 500 futures (ESH23) are trending down -0.08% this morning after three major U.S. benchmark indices closed lower for a fourth straight session, with Nasdaq dropping the most as market participants'...

ESH23 : 3,957.05s (-0.09%)
META : 295.73 (-1.31%)
ICCM : 0.6600 (+14.78%)
LCID : 5.17 (-5.14%)
SLNO : 4.11 (+0.12%)
TERN : 5.31 (+3.71%)
SMCI : 231.54 (-4.74%)
Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why

Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.

CPRX : 12.13 (-0.41%)
AERI : 15.25 (+0.07%)
SLNO : 4.11 (+0.12%)
ACER : 0.8303 (-0.25%)
Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA

Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.

CPRX : 12.13 (-0.41%)
AERI : 15.25 (+0.07%)
SLNO : 4.11 (+0.12%)
ACER : 0.8303 (-0.25%)
Feneca (FENC) Gets FDA Nod for Cancer-Related Hearing Loss Drug

Feneca Pharmaceuticals (FENC) receives FDA approval for Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors.

AERI : 15.25 (+0.07%)
FENC : 7.33 (-3.81%)
SLNO : 4.11 (+0.12%)
ACER : 0.8303 (-0.25%)
Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval

Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.

AERI : 15.25 (+0.07%)
AUPH : 8.27 (-0.84%)
SLNO : 4.11 (+0.12%)
ACER : 0.8303 (-0.25%)
Spectrum Pharmaceuticals (SPPI) Gets Nod for Rolvedon Injection

Spectrum Pharmaceuticals (SPPI) receives FDA approval for its drug candidate, Rolvedon (eflapergrastim), for treating chemotherapy-induced neutropenia.

SPPI : 1.0300 (unch)
CPRX : 12.13 (-0.41%)
AERI : 15.25 (+0.07%)
SLNO : 4.11 (+0.12%)
Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma

Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.

CPRX : 12.13 (-0.41%)
AERI : 15.25 (+0.07%)
SLNO : 4.11 (+0.12%)
VIRX : 1.1100 (-0.89%)
Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds

Ironwood (IRWD) reports positive top-line data from a late-stage study evaluating Linzess (linaclotide) for functional constipation in pediatric patients aged six to 17 years.

IRWD : 9.41 (+2.51%)
ABBV : 153.43 (-0.12%)
CPRX : 12.13 (-0.41%)
SLNO : 4.11 (+0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories and Serenz Nasal Relief....

See More

Key Turning Points

3rd Resistance Point 4.71
2nd Resistance Point 4.53
1st Resistance Point 4.32
Last Price 4.11
1st Support Level 3.93
2nd Support Level 3.75
3rd Support Level 3.54

See More

52-Week High 6.20
Fibonacci 61.8% 4.16
Last Price 4.11
Fibonacci 50% 3.52
Fibonacci 38.2% 2.89
52-Week Low 0.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar